Infinity Pharmaceuticals Inc
NASDAQ:INFI
Infinity Pharmaceuticals Inc
NASDAQ:INFI
Price:
0.0037 USD
Market Closed
Updated:
Apr 29, 2024
Section:
Relative Value
The Relative Value of one
INFI
stock under the Base Case scenario is
0.411
USD.
Compared to the current market price of 0.0037 USD,
Infinity Pharmaceuticals Inc
is
Undervalued by 99%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
INFI
Relative Value
Base Case
0.411
USD
Undervaluation 99%
Valuation Multiples
Multiples Across Competitors
INFI Competitors Multiples
Infinity Pharmaceuticals Inc Competitors
Infinity Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Infinity Pharmaceuticals Inc
NASDAQ:INFI
|
335.8k USD | 0.1 | -0 | 0.4 | 0.4 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
146.2B USD | 5.2 | 21.8 | 16.2 | 24.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102B USD | 10.3 | 28.2 | 22.5 | 23.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.7B USD | 7.5 | 24.7 | 16.3 | 18 | |
| AU |
|
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
82.9B USD | 3.1 | 14.6 | 8 | 10.3 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
42.4B USD | 6.2 | -9 | -9.5 | -8.1 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.1T KRW | 17.5 | 71.1 | 43.5 | 59.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
